Medical treatment of levodopa-induced dyskinesias

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Rascol, O ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADROGOLIDE; AMANTADINE; BROMOCRIPTINE; BUSPIRONE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ESTROGEN; FLUOXETINE; IDAZOXAN; IFENPRODIL; KAPPA OPIATE RECEPTOR ANTAGONIST; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAXAGOLIDE; OXIPEROMIDE; PHYSOSTIGMINE; PRAMIPEXOLE; PROPRANOLOL; RAUWOLSCINE; RITANSERIN; ROPINIROLE; SELEGILINE; SEROTONIN ANTAGONIST; TERGURIDE; TIAPRIDE; YOHIMBINE;

BASAL GANGLION; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CONFERENCE PAPER; DRUG INDUCED DISEASE; DYSKINESIA; EMBRYO CELL; HUMAN; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS;

AMANTADINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0034126269     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. Tanner C. Drug-induced movement disorders (tardive dyskinesia and dopa-induced dyskinesia). In: Vinken PJ, Bruyn GW, Klawans HL, eds. Extrapyramidal disorders, revised series 5 (Handbook of clinical neurology, Vol. 49). Amsterdam: Elsevier Science, 1986:185-204
2. Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124
3. Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994;9:2-12
4. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394
5. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesias in Parkinson's disease. Mov Disord 1998;13:871-876
6. Nutt JG, Woodward WR, Carter JH, Gaucher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to the on-off phenomenon. Arch Neurol 1992;49:1123-1130
7. Maratos E, Smith L, Jackson MJ, et al. Inducing dyskinesias in MPTP-treated common marmosets: the effects of repeated treatment with combinations of L-dopa and ropinirole. Neurology 1998;50(4 Suppl 4):A135 (Abstract)
8. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55:S1-S9
9. Parkinson Study Group. Effects of tocopherol and deptenyl on the progression of disability in early Parkinson's disease. Ann Neurol 1993;328:176-183
10. Parkinson Study Group. Impact of deprenyl and tocopherol treatment in Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45
11. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicentre 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-27
12. Rascol A, Guiraud B, Montastruc JL, et al. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150
13. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neursurg Psychiatry 1981;44:1020-1023
14. 3H] spiperone binding. Brain Res 1986;379:294-299
15. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:196-198
16. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038
17. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:257-262
18. Rinne UK, Bracco F, Chouza C, et al. and the Parkinson's Disease Study Group. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998;55(Suppl 1): S23-S30
19. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45
20. Weiner WJ, Koller WC, Perlik S, et al. Drug holiday and management of Parkinson's disease. Neurology 1980;30:1257-1261
21. Goetz CG, Tanner CM, Klawans HL. Drug holiday in the management of Parkinson's disease. Clin Neuropharmacol 1982;5:351-364
22. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease: continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550
23. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanism by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23
24. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781
25. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170
26. Poewe W, Kleedorfer B, Wagner M, et al. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology. New York: Raven Press, 1993;60:656-659
27. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576
28. Limousin P, Pollak P, Benazzouz A, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345(8942):91-95
29. Agid Y. Levodopa. Is toxicity a myth? Neurology 1998;50:858-863
30. Defer GL, Geny C, Ricolfi F, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. Clinical approach. Brain 1996;119:41-50
31. Lopez-Lozano JJ, Bravo G, Brera B, et al., and the Clinica Puerta de Hierro Neural Transplantation Group. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. J Neurosurg 1997;86: 931-942
32. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744
33. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Clinical implications. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992:411-431
34. Tarsy D, Parkes JD, Marsden CD. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1975;38:331-335
35. Klawans HL, Weiner WJ. Attempted use of haloperidol in the treatment of L-dopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1974;37:427-430
36. Ekesbo A, Andren PE, Gunne LM, Tedroft J. (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport 1997;8:2567-2570
37. Brücke T, Bankeiwicz K, Harvey-White J, Kopin I. The partial dopamine agonist terguride in the MPTP-induced hemiparkinsonian monkey model. Eur J Pharmacol 1988;148:445-448
38. Cotsini GU, Bonucelli U, Rainer E, Del Zompo M. Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J Neural Transm 1985;64:105-111
39. Tetsuo A, Yamaguchi M, Mizuta E, Kunos S. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 1993;33:507-511
40. Baronti F, Mouradian MM, Conant KE, et al. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 1992;42:1241-1243
41. Critchley P, Parkes D. Transdihydrolisuride in parkinsonism. Clin Neuropharmacol 1987;10:57-64
42. Murray AM, Waddington JL. The interaction of clozapine with dopamine D1 versus D2 receptor-mediated function: behavioural indices. Eur J Pharmacol 1990;186:79-86
43. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-1555
44. Bennett JP, Jr, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-411
45. Durif F, Vidailhet M, Assal F, et al. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997;48:658-662
46. Gomez-Mancilla B, Bédard P. Effect of chronic treatment with (+)-PHNO, a D-2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188
47. Luquin MR, Laguna J, Obeso JA. Selective D-2 receptor stimulation induces dyskinesias in parkinsonian monkeys. Ann Neurol 1992;31:551-554
48. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopaminc receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279
49. Grondin R, Bédard PJ, Britton DR, Shiosaki K. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997;49:421-426
50. Rascol O, Blin O, Descombes S, et al. ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology 1997;48:269-270
51. Rascol O, Blin O, Wright S, et al. A double-blind comparison of ABT-431, a selective, full dopamine D1 receptor agonist, with levodopa in the treatment of advanced Parkinson's disease [abstract]. Neurology 1998;50(4 Suppl 4):A70
52. Bordet R, Kidray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-3367
53. Blanchet PJ, Konitsiotis S, Chase T. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed MPTP monkeys. J Pharmacol Exp Ther 1997;283:794-799
54. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997;49:231-252
55. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118
56. Engber TM, Boldry RC, Kuo S, Chase TN. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dymorphin and enkephalin. Brain Res 1992;581:261-268
57. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588
58. Grefen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432
59. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578
60. Kornhuber J, Bormann J, Hubers M, et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human post-mortem brain study. Eur J Pharmacol 1991;206:297-300
61. Kornhuber J, Quack G, Danysz W. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;35:713-721
62. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000;47(suppl 1):S122-S130
63. Rajput AH, Rajput A, Lang AE, et al. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998;13:851 (Letter)
64. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326
65. Montastruc JL, Rascol O, Senard JM. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci Biobehav Rev 1997;21:477-480
66. Verhagen Metman L, Blanchet PJ, van den Munckhof P, et al. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998;13:414-417
67. Verhagen Metman L, Del Dotto P, Natte R, et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206
68. Lacomblez L, Bensimon G, Leigh PN, et al., for the Amyotrophic Lateral-Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431
69. Bryson HM, Fulton B, Benfield P. Riluzole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996;52:549-563
70. Dray A, Davies J, Oakley NR, et al. The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioral observations. Brain Res 1978;151:431-432
71. Costall B, Fortune DH, Naylor RJ, et al. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975;14:859-868
72. Mengod G, Nguyen H, Le H, et al. The distribution and cellular localization of the serotonin IC receptor mRNA in the rodent brain examined by in situ hybridization histochemistry: comparison with receptor binding distribution. Neuroscience 1990;35:577-591
73. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain - III: autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987;21:97-122
74. Fox SM, Moser B, Brotchie JM. Behavioral effects of 5HT2c receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinsons disease. Exp Neurol 1998;151:35-49
75. Meco G, Marini S, Lestingi L, et al. Controlled single-blind cross-over study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson's disease. Curr Ther Res 1988;43:262-270
76. Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858
77. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
78. Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991;6:51-58
79. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus coeruleus. Clin Neuropharmacol 1986;9:373-378
80. Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991;54:376-377
81. Bonifati V, Fabrizio E, Cipriani R, et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82
82. Hammerstad JP, Carter J, Nutt JC, et al. Buspirone in Parkinson's disease. Clin Neuropharmacol 1986;9:556-560
83. Gomez-Mancilla B, Bédard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427
84. Henry B, Plowright A, Fox SH, et al. Alpha-2-adrenergic antagonists reduce symptoms in animal models of L-dopa-induced dyskinesias. Soc Neurosci Abstr 1997;23:742 (Abstract)
85. Rascol O, Arnulf I, Brefel C, et al. L-Dopa induced dyskinesias improvement by an alpha-2 antagonist, idazoxan, in patients with Parkinson's disease. Mov Disord 1997;12:511
86. Brefel-Courbon C, Thalamas C, Peyro Saint Paul H, et al. Alpha-2 adrenoceptor antagonists. A new approach to Parkinson's disease? CNS Drugs 1998;10:189-207
87. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:149-158
88. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726
89. Newman DD, Rajakumar N, Flumerfelt B, Stoesse AJ. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. Neuroreport 1997;8:669-672
90. Trabucchi M, Bassi S, Frattola L. Effects of naloxone on the 'on-off' syndrome in patients receiving long-term levodopa therapy. Arch Neurol 1982;39:120-121
91. Sandyk R, Snider SR. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry 1986;143:118 (Letter)
92. Nutt JC, Rosin AJ, Eisler T, et al. Effect of an opiate antagonist on movement disorders. Arch Neurol 1978;35:810-811
93. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440
94. Schiffman SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RD C8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067
95. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesias in parkinsonian monkeys. Ann Neurol 1998;43:507-513
96. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesias by propranolol in Parkinson's disease. Neurology 1996;46:1548-1551
97. Mendez JS, Cotzias CC, Mena I, Papavasiliou PS. Diphenylhydantoin. Blocking of levodopa effects. Arch Neurol 1975;32:44-46
98. Gomez-Mancilla B, Bédard PJ. Effect of oestrogen and progesterone on L-dopa-induced dyskinesias in MPTP-treated monkeys. Neurosci Lett 1992;135:129-132
99. Bédard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977;2:1367-1368
100. Tarsy D, Leopold N, Sax DS. Physostigmine in choreiform movement disorders. Neurology 1974;24:28-33